Trial Profile

Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 21 Feb 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Alogliptin (Primary)
Indications Type 2 diabetes mellitus
Focus Therapeutic Use
Acronyms SPEAD-A

Most Recent Events

01 Feb 2018 Results of post hoc subanalysis (n=322) evaluating the effect of alogliptin on the longitudinal change in GSM in patients with type 2 diabetes, published in the Diabetes Therapy
25 Mar 2016 Status changed from active, no longer recruiting to completed.
01 Dec 2015 Results published in the Diabetes Care

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com